Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
Advances in treatment modalities for osteo-, and chondro-sarcomas (OCSs)contributes to their disease outcomes, whereas these have been still unsatisfactory in metastatic tumors of OCS. We identified overexpression of lincRNA-ARF6 OCSs cell lines with high metastatic potentiality. The lincRNA-ARF6 regulated ARF6 expression, but not related with motility and invasion of these cell lines. Further studies will be needed for contribution of non-coding RNA in OCSs metastasis.
|